Levetiracetam Ethypharm (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, which modulates neurotransmitter release. This action stabilizes neuronal membranes and decreases excessive neuronal excitability, thereby preventing the spread of epileptic activity across the brain.

The dosage of levetiracetam is individualized by the prescribing clinician based on the patient’s age, weight, renal function, and seizure type. The prescriber determines the appropriate infusion rate and total daily amount according to clinical guidelines.

Safety data for levetiracetam in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and decisions are made in consultation with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Levetiracetam has a distinct mechanism targeting SV2A and exhibits fewer drug‑enzyme interactions compared with many older antiepileptics such as carbamazepine or phenytoin. This profile often results in a more predictable pharmacokinetic behavior and may simplify combination therapy, though individual response varies.

Levetiracetam Ethypharm should be stored at ambient temperature, below 25 °C, in its original packaging to protect from moisture and light. Do not freeze the solution, and ensure the container remains sealed until use.

Levetiracetam Ethypharm is given intravenously by slow infusion under the supervision of qualified healthcare personnel. The infusion rate and total daily dose are determined by the prescribing physician based on the patient’s clinical condition.

Serious risks include severe allergic reactions such as anaphylaxis, life‑threatening skin conditions like Stevens‑Johnson syndrome, blood dyscrasias, and the emergence of suicidal thoughts or behaviors. Patients should be monitored closely for any of these events, especially during treatment initiation.

Levetiracetam is contraindicated in individuals with known hypersensitivity to levetiracetam or any of its excipients. Caution is also advised for patients with severe renal impairment who have not had dose adjustments, and for those with a history of serious psychiatric reactions.